Biblio
Found 35 results
“Accelerated Access to Innovative Medicines for Patients in Need”, Clinical Pharmacology & Therapeutics, vol. 96, pp. 559–571, 2014.
, “Access and availability of orphan drugs in the United States: advances or cruel hoaxes?”, Expert Opinion on Orphan Drugs, vol. 2, pp. 1147-1150, 2014.
, “A community consultation survey to evaluate support for and success of the IMMEDIATE trial”, Clinical Trials, vol. 11, pp. 178-186, 2014.
, “The Janus initiative: A multi-stakeholder process and tool set for facilitating and quantifying Adaptive Licensing discussions”, Health Policy and Technology, vol. 3, pp. 241 - 247, 2014.
, “Adaptive licensing: creating a safe haven for discussions”, Scrip Regulatory Affairs, 2013.
, “Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development”, Therapeutic Innovation & Regulatory Science, vol. 47, pp. 474-483, 2013.
, “Curing Consortium Fatigue”, Science Translational Medicine, vol. 5, pp. 200fs35–200fs35, 2013.
, “Legal Foundations of Adaptive Licensing”, Clinical Pharmacology & Therapeutics, vol. 94, pp. 309–311, 2013.
, “Adaptive licensing: taking the next step in the evolution of drug approval.”, Clin Pharmacol Ther, vol. 91, no. 3, pp. 426-37, 2012.
, “The future of drug development: advancing clinical trial design”, Nat Rev Drug Discov, vol. 8, no. 12, pp. 949 - 957, 2009.
,